You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Drug Sales Trends for BENICAR


✉ Email this page to a colleague

« Back to Dashboard


Drug Sales Revenue Trends for BENICAR
Drug Units Sold Trends for BENICAR

Annual Sales Revenues and Units Sold for BENICAR

These sales figures are drawn from a US national survey of drug expenditures
Drug NameRevenues (USD)UnitsYear
BENICAR ⤷  Subscribe ⤷  Subscribe 2021
BENICAR ⤷  Subscribe ⤷  Subscribe 2020
BENICAR ⤷  Subscribe ⤷  Subscribe 2019
BENICAR ⤷  Subscribe ⤷  Subscribe 2018
BENICAR ⤷  Subscribe ⤷  Subscribe 2017
BENICAR ⤷  Subscribe ⤷  Subscribe 2016
>Drug Name>Revenues (USD)>Units>Year
Showing 1 to 6 of 6 entries

Market Analysis and Sales Projections for Benicar

Introduction to Benicar

Benicar, also known by its generic name olmesartan medoxomil, is a medication used to treat high blood pressure. It is one of the most popular antihypertension drugs in the United States, marketed by Daiichi Sankyo.

Market Size and Demand

The market for hypertension treatments is substantial, with approximately 73 million people in the U.S. aged 20 and older suffering from hypertension. Of these, about 61% (around 45 million people) are under treatment, making Benicar a significant player in this market[1].

Historical Sales Performance

Before the expiration of its patent, Benicar was a highly lucrative drug for Daiichi Sankyo. For the 12 months ending August 31, 2016, Benicar generated approximately $1 billion in U.S. sales, while its combination drug, Benicar HCT, earned around $805 million during the same period[4].

Impact of Generic Versions

The approval of generic versions of olmesartan medoxomil in 2016 significantly impacted the sales of Benicar. Generic drugs are typically cheaper and can capture a significant portion of the market, reducing the sales of the branded version. This shift has likely reduced the revenue generated by Benicar since the introduction of generics[4].

Sales Projections Post-Patent Expiration

Following the patent expiration, the sales of Benicar have declined as generic alternatives have become more prevalent. While Daiichi Sankyo initially raised forecasts for the Benicar franchise due to strong demand, the introduction of generics has since reduced the company's reliance on this drug for revenue growth[3][4].

Current Market Status

As of recent years, Daiichi Sankyo has focused on other products to drive sales growth. The company has seen significant success with other medications, such as ENHERTU®, which has contributed substantially to their revenue. However, Benicar remains a part of their product portfolio, albeit with reduced market share and sales compared to its peak[2].

Competitive Landscape

The antihypertension market is highly competitive, with numerous drugs available. Benicar, once a market leader, now faces intense competition from generic versions of olmesartan medoxomil and other branded antihypertension medications. This competition has further eroded Benicar's market share and sales[1][4].

Regulatory and Legal Implications

Benicar has been involved in several lawsuits related to its side effects, particularly the risk of villous atrophy, a condition that can lead to severe gastrointestinal symptoms. These legal issues have also impacted the drug's reputation and sales[1].

Global Sales and Market Share

While Benicar's sales have declined in the U.S. market, Daiichi Sankyo continues to sell the drug globally. However, the overall sales figures for Benicar are no longer as robust as they were before the patent expiration and the introduction of generic versions[3].

Future Outlook

Given the current market dynamics, the future sales projections for Benicar are modest. The drug will likely continue to be prescribed, but its market share and sales will remain under pressure from generic alternatives and other competing antihypertension medications.

Key Statistics

  • U.S. Sales (2016): Approximately $1 billion for Benicar and $805 million for Benicar HCT[4].
  • Market Size: Approximately 73 million people in the U.S. aged 20 and older suffer from hypertension[1].
  • Generic Impact: Approval of generic versions in 2016 significantly reduced Benicar's sales[4].

Conclusion

Benicar, once a dominant player in the antihypertension market, has seen its sales and market share decline significantly since the introduction of generic versions and the expiration of its patent. While it remains part of Daiichi Sankyo's product portfolio, its future sales projections are modest due to intense competition and the availability of cheaper generic alternatives.

Key Takeaways

  • Benicar was a highly lucrative drug before its patent expiration.
  • The introduction of generic versions significantly reduced its sales.
  • The drug faces intense competition in the antihypertension market.
  • Legal issues related to side effects have further impacted its sales.
  • Future sales projections are modest due to market competition.

FAQs

Q: What is Benicar used for? A: Benicar, or olmesartan medoxomil, is used to treat high blood pressure.

Q: How has the introduction of generic versions affected Benicar's sales? A: The introduction of generic versions has significantly reduced Benicar's sales, as generics are typically cheaper and capture a large market share.

Q: What are some of the side effects associated with Benicar? A: Benicar has been linked to villous atrophy, a condition that can cause severe gastrointestinal symptoms.

Q: How does Benicar compare to other antihypertension medications in terms of market share? A: Benicar's market share has declined due to competition from generic versions and other branded antihypertension medications.

Q: What is the current outlook for Benicar's sales? A: The future sales projections for Benicar are modest due to intense market competition and the availability of generic alternatives.

Sources

  1. The Cochran Firm - What are the Problems With Benicar?
  2. Daiichi Sankyo - FY2023 Financial Results Presentation
  3. S&P Global - Astellas and Daiichi Sankyo Revise Upwards in H1
  4. Managed Healthcare Executive - First olmesartan generics approved for hypertension

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.